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Objectives: Osteoarthritis (OA) is the most common and costly bone and joint 
disease in the elderly. Recently, viscosupplementation, an intra-articular injection 
of artificial joint fluid in order to restore rheological properties affecting lubrica-
tion and shock absorption, has introduced as an alternative conservative treat-
ment. To assess the effectiveness and cost-effectiveness of Hylan G-F 20 (Hylan) as 
a substitute for existing treatments for pain due to OA of the knee, other viscosup-
plementation devices, and/or as an adjunct to conventional therapy. MethOds: A 
Markov microsimulation model was developed to define a treatment pathway for 
OA of the knee, illustrate the current costs of treating patients with the condition, 
and demonstrate the potential savings associated with introduction of Hylan. 
A hypothetical cohort of patients categorized as having 2-3 or 4 degree of OA of 
the knee was followed over a 30-month time period. Results: When compar-
ing intra-articular administration of Hylan, the use of NSAIDs and intra-articular 
administration of corticosteroids (GCS), rirost costs compared with the strategy 
of NSAIDs amounted to $192 rate per 1 patient. This increase in efficiency of 20% 
in favor of Hylan. Accordingly, the ratio ICER was $979 per patient, which is much 
below the threshold of “society’s willingness to pay.” Markov cycle for patients 
with OA of the knee of 4 degrees showed that use of Hylan is more effective in the 
end point of modeling the effectiveness of this strategy was 12% (compared to 
0% in the policies of NSAIDs and corticosteroids). We calculated the total cost of 
the budget in the application of NSAIDs, GCS, and Hylan, after calculations found 
that the use of Gilan can save significant budget funds - up to $954582 (for 1,000 
patients). cOnclusiOns: Hylan may delay the need for joint replacement in 
patients with OA of 4 degrees, suggest its use is justified from a clinical and eco-
nomic standpoint as compared to the consideration of other treatment strategies.
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Objectives: Failed back surgery syndrome (FBSS) represents one main cause 
of chronic neuropathic or mixed pain and functional disability. Results from 
previous clinical trials and from the PRECISE naturalistic study [Zucco et al, 
Neuromodulation, 2015] show that Spinal Cord Stimulation (SCS) provides pain 
relief and improves patients’ health. Our current aim is to understand the rela-
tionship between pain intensity, functional disability, and overall Health-Related 
Quality-of-life (HRQoL). MethOds: At recruitment (before SCS) and every 6 
months for 2 years after SCS a battery of questionnaires/tests were completed: 
EQ-5D-3L and SF-36 for HRQoL, the Numerical Rating Scale (NRS) to measure pain 
intensity, and the Oswestry Disability Index (ODI) to measure disability/functional 
capability. Statistical tests were conducted to compare the HRQoL levels (using the 
EQ-5D utility index, the EQ-VAS, the SF-36 Physical Component Summary (PCS) 
and Mental Component Summary (MCS) index), NRS and ODI at baseline with 
those measured during the observational period. Multilevel regression analyses 
were conducted to investigate the association between the HRQOL indexes and 
the NRS and ODI indexes, on adjusting for: age, gender, previous surgery, educa-
tion, baseline level of the dependent variable, and time of assessment. Results: 
Eighty patients (40% male, mean age= 58 years) participated. Significant improve-
ments (p< 0.001) in pain intensity, functional capability and HRQoL were reached 
after 6 months from SCS and maintained or further improved until the end of 
the observational period. According to the regression models, every HRQoL index 
was significantly associated (p< 0.001) with both the NRS and the ODI indexes 
at any time of assessment. cOnclusiOns: Our results suggest that in a 2-year 
observational period, SCS+CMM treatment reduces significantly pain intensity and 
functional disability in patients with FBSS, with significant repercussions on their 
general HRQOL. Furthermore, our results suggest the HRQoL instruments used in 
this study are valid to assess overall patients’ health and treatment outcomes.
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Objectives: Effective but expensive (approximately € 14,000 per year) tumor 
necrosis factor inhibiting drugs (TNFi) are used for the treatment of several chronic 
inflammatory diseases including rheumatoid arthritis (RA). A proven dose reduc-
tion strategy in RA patients could result in substantial cost savings. It may however 
also lead to a loss of quality of life as a result of flares induced by dose reduction 
attempts. If this loss is compensated with large cost saving, we might still consider 
the intervention cost-effective. MethOds: a pre-planned cost-effectiveness analy-
sis of the DRESS study, a randomised controlled, non-inferiority trial comparing a 
disease activity guided dose optimisation strategy with usual care in patients with 
RA and low disease activity using TNFi. Total health care costs were measured and 
quality adjusted life years (QALY) were based on EQ5d utilities. Decremental cost-
effectiveness ratio and incremental net monetary benefit (iNMB) were determined. 
of the Psoriatic Arthritis Response Criteria, Health Assessment Questionnaire 
and Psoriasis Area and Severity Index data, synthesized from published clini-
cal trials via a Bayesian network meta-analysis. Following a payer perspective, 
direct costs relating to drug acquisition, administration, monitoring and overall 
patient management were considered (2015). Results: All anti-TNF therapies 
yielded greater improvements in the aforementioned efficacy outcomes and in 
terms of quality-adjusted life years (QALYs) compared to SoC. The incremental 
cost per QALY gained of CZP relative to SoC was € 16,539 and € 20,714 at 12- and 
24-week response assessment period respectively, which is below the established 
willingness-to-pay threshold of € 34,000. Between the anti-TNFs, efficacy differ-
ences did not reach statistical significance. In terms of the mean lifetime patient 
cost, it ranged from € 61,469 for CZP to € 86,632 for infliximab, assuming a 12-week 
response assessment period. Similarly, at the alternative assessment period sce-
nario, it ranged from € 66,401 and € 67,499 for golimumab and CZP respectively, to 
€ 83,483 for infliximab. cOnclusiOns: CZP was found to be cost-effective relative 
to SoC and as effective in terms of efficacy and less costly, i.e. dominant, compared 
to most other licensed anti-TNF agents in Greece.
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Objectives: A Telerehabilitation service following Total Knee Replacement (TKR) 
has been shown to be not inferior to standard rehabilitation (SR) in recovering the 
active knee flexion range of motion (ROM) in patients who had not complication 
related to TKR surgery. However, little is known about its cost-effectiveness. The 
objective of this economic evaluation was to assess cost-effectiveness of telereha-
bilitation versus SR. MethOds: A Markov model was employed to simulate the 
natural progression of TKR, assuming telerehabilitation does not influence this. 
The revision risk was calculated from patient-level data (multicentre KAT trial) 
employing a parametric model including established prognostic factors. The others 
state-transition probabilities and treatments effects were obtained from published 
literature. Rehabilitation and transportation costs were assessed adopting Ita-
NHS perspective employing Italian tariffs. The patients without complications 
followed the TR-SR programme receiving half of the sessions in SR and half in 
telerehabilitation regime. Patients with any complication followed the SR receiv-
ing face-to-face sessions. Results were adjusted applying an annual discount rate 
of 3% and half-cycle correction. Probabilistic sensitivity analysis (PSA) described 
the parameters uncertainty. Results: A cohort of 1000 patients with the features 
of KAT trial population (70 years old, 44% male and 19% had any complication 
related to the surgery) were first assigned to SR then to TR -SR. The mean (SE) 
lifetime healthcare cost in SR arm were € 1,033.81 (€ 21.97) and € 818.44 (€ 13.82) for 
telerehabilitation (mean±95%CI difference -215.33±€ 10.64). Mean (SE) ROM was 
16.68 (0.04) in SR programme and 18.84 (0.04) in telerehabilitation programme 
(mean±95%CI difference 2.16±0.09). The probability that telerehabilitation is cost-
saving (WTP:€ 0) is 92%. cOnclusiOns: Adopting the healthcare provider per-
spective, TR-SR seems cost-effective when compared to a SR programme. Further 
sensitivity analyses are required to relax the model assumptions and to assess 
the robustness of the model.
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Objectives: This study aims to evaluate the cost-effectiveness of Tocilizumab-
based-regimen and other four biologic-based-regimens for the treatments of 
DMARD-IR rheumatoid arthritis patients in China. MethOds: A network meta-
analysis (NMA) was performed to combine and compare ACR response rates across 
all relevant RCT evidences. The real-world treatment fees, including drugs, monitor-
ing and administration fees, were collected through expert interviews in Beijing, 
Shanghai, Guangzhou and Chengdu city. All Patient-Assistant-Programs were con-
sidered in drug-cost calculation. The cost-effectiveness analysis was conducted to 
evaluate average costs per ACR20/50/70 response among five regimens. Results: 
The NMA analysis included 28 eligible RCTs. The results indicated that ACR20/50/70 
response rates of Tocilizumab-based-regimen were 74%, 56% and 28% respectively. 
While the ACR20/50/70 response rates of other four regimens (Adalimumab, 
Infliximab, Etanercept and Etanercept-NCB (Non-Comparable-Biologics)) were 77%, 
55% and 19% respectively. The total treatment fees of these five regimens within 
48-weeks were calculated to be RMB 87,384, RMB 113,162, RMB 82,386, RMB 154,894 
and RMB 93,582. The cost-effectiveness results demonstrated that, compared 
with other four regimens, Tocilizumab-regimen cost the average of RMB 312,087 
(USD50,336) to achieve an ACR70 response. It cost RMB 118,087 (USD19,046) per 
ACR20 response and RMB 156,044 (USD25,168) per ACR50 response, which were 
comparable with Infliximab-regimen, but less than others. Tocilizumab could save 
costs ranged from RMB 3,449 (USD556) to RMB 503,147 (USD81,152) in order to fully 
achieve ACR20/50/70 response rates compared with other regimens. cOnclusiOns: 
The study demonstrated that, compared with other available biologicals in China, 
Tocilizumab-regimen was the most cost-effective to achieve ultimate ACR70 
response for DMARD-IR rheumatoid arthritis patients. It also suggested that it had 
similar cost-effectiveness results to Infliximab to achieve ACR20/50 responses.
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could influence the cost and quality of life of patients. To assess the cost-effectiveness 
of adding a PPI compared to no PPI co-treatment in older patients LDASA. MethOds: 
A cost-effectiveness study was conducted with a Markov model for PPI co-medication 
(intervention) compared to no PPI co-medication (usual care) in LDASA users. The 
base case analysis was performed for patients of 70 years old. The models addressed 
chronic LDASA use of five years. Incremental cost-utility ratio’s (ICURs), expressed as 
costs per QALY gained, were calculated for different age categories (60 up to 80 years) 
accounting for different risk rates for side effects from LDASA or PPI use. These side 
effects included gastrointestinal bleeding, dyspepsia, pneumonia and hip fractures. 
Finally, a budget impact analysis was performed to assess the health care expen-
ditures to add PPIs in all current patients using LDASA above the age of 60 years 
in the Netherlands. Results: Adding a PPI to LDASA, compared to not adding a 
PPI, resulted in incremental costs of € 71,84 and incremental effects of 0,006 QALY’s 
and an ICUR of € 11,491.53/QALY gained for the base case analysis. The ICUR for 60- 
and 80-year old patients was € 11,491.53/QALY and € 53,860.85/QALY, respectively. 
The total budget impact of adding a PPI to current LDASA users (≥ 60 years) was 
€ 174,475,296. cOnclusiOns: Adding a PPI to LDASA users may be a cost-effective 
approach in patients from 60 up to 80 years old. However, with increasing age the costs 
became higher and the effects lower, due to higher risks of the different side effects.
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Objectives: The objective of this study was to analyze the cost-effectiveness of bio-
logics compared to conventional disease-modifying antirheumatic drugs (cDMARDs) 
for the treatment of rheumatoid arthritis (RA) using real world data from Finnish 
national registers. MethOds: RA patients starting their first biologics 2007 - 2011 and 
comparator patients using cDMARDs during the same time period were obtained from 
the National register of biologic treatments in Finland (ROB-FIN) and from the Central 
Finland Central Hospital (CFCH) patient records. Medication changes were allowed 
and patients were followed up to two years. Propensity score matching was applied 
to adjust difference between biologics and cDMARD users. Effectiveness in quality 
adjusted life years (QALY) was based on ROB-FIN and CFCH patient records while the 
direct costs of medication and health care utilization were obtained from relevant 
Finnish national registers. Mean costs and effectiveness as well as 95% confidence 
intervals were calculated using bootstrap resampling approach. Both the costs and 
effectiveness were discounted at 3%. Results: Of 1487 patients RA patients meeting 
study inclusion criteria, 608 biologic users and 300 cDMARD users were included in 
analyses after propensity score matching. Mean follow up times were 463 and 538 
days for biologic users and cDMARD users, respectively. Mean costs for biologics and 
cDMARDs were 57,900 € (CI 95% 54,800 - 60,900 € ) and 21,900 € (CI 95% 17,300 - 26,500 
€ ), while mean effectiveness was 1.2064 (CI 95% 1.1756 -1.2373) and 1.2066 QALYs 
(CI 95% 1.1751 -1.2381), respectively. cOnclusiOns: The high cost of biologics and 
the small, non-significant difference in effectiveness for the advantage of cDMARDs 
resulted in cDMARDs being dominant treatment. However, regardless the propensity 
score matching, latent confounders may introduce bias to the results.
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Objectives: To evaluate the relative health gains and costs of secondary preven-
tion of fractures with generic alendronate, risedronate, denosumab and zoledronic 
acid. MethOds: We evaluated the cost-effectiveness based on a previously devel-
oped decision analytic fracture model. The model synthesizes available data on the 
epidemiology of fractures and related mortality, need for long-term care and home 
based assistance. The model is set up as an individual level Markov model and out-
puts include number of quality adjusted life years (QALYs) and costs. Effectiveness 
data were gathered from a recent systematic review and costs were collected from 
publicly available sources. We preformed analyses for women 85 years old with a 
previous hip fracture. In this first preliminary analysis, we assumed full compliance 
and lifelong treatment. Results: Zoledronic acid was the most effective alternative, 
followed by denosumab, risedronate, generic alendronate and no treatment, yield-
ing respectively 4.7661, 4.7640, 4.6715, 4.1581 and 3.8915 QALYs. In terms of costs, 
generic alendronate was the best options, being less costly than no secondary pre-
vention. In terms of cost-effectiveness, no treatment, denosumab and risedronate 
were excluded based on dominance, seeing that alendronate was more effective and 
less costly than no treatment, and zoledronic acid was more effective and less costly 
than both denosumab and risedronate. Compared to alendronate, zoledronic acid 
yields an incremental cost-effectiveness ratio of $48,832 per QALY. cOnclusiOns: 
All options are effective compared to no treatment. In terms of comparative effec-
tiveness and cost-effectiveness, our analysis indicates that zoledronic acid is the 
optimal strategy for secondary prevention, assuming a cost-effectiveness threshold 
of $50,000 per QALY gained.
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Bootstrap analyses with 1000 replications were used. Results: 180 patients were 
included; 121 were allocated to the dose optimisation strategy, 59 to control. The 
dose optimisation strategy resulted in mean cost savings of -€ 12,280 (95 percentile 
-€ 10,502; -€ 14,104) per patient. There is a 84% chance that the dose optimisation 
strategy results in QALY loss with a mean loss of -0.02 (-0.07; 0.02). When using a 
willingness to pay (WTP) level of € 80,000 per QALY, the mean iNMB is € 10,467 (€ 6,553; 
€ 14,037) per patient per 18 months. Sensitivity analyses using prices -30% and -50% 
still resulted in a cost effective strategy. cOnclusiOns: Disease activity guided 
dose optimisation of TNFi results in considerable cost savings with no relevant loss 
of quality of life. When the minimal QALY loss is compensated with the upper limit 
of what society is willing to pay in Netherlands, the net savings are still high, even 
when future price drops are taken into account.
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Objectives: To determine the cost-utility of ustekinumab (UST) administered sub-
cutaneously every 12 weeks (after induction), compared with adalimumab (ADA) 
administered subcutaneously every two weeks, and infliximab (INF), administered 
intravenously every eight weeks (after induction) in treating moderate-to-severe 
psoriatic arthritis (PsA) in Russia. MethOds: A Markov model was developed with 
expert panel input. Biologic-naïve patients entered the model, progressing over 
the 10-year analytic horizon in annual cycles according to observed transition 
probabilities. Six sequences of 1st line/2nd line/3rd line treatment were simulated: 
UST/ADA/INF, UST/INF/ADA, ADA/UST/INF, ADA/INF/UST, INF/ADA/UST, and INF/
UST/ADA, with best supportive care used when all three failed. Retention rates 
were extracted from PSOLAR database. Utilities for UST successes/failures were 
derived directly from PSUMMIT-1&2 trials using the HAQ-DI mapped to EQ-5D using 
Rodgers’ equation; INF and ADA utilities were obtained from Yang’s NICE submission 
(2012). Costs from the Russian Ministry of Health perspective were obtained from 
standard lists, converted to 2014 euros and discounted at 5%, as per Russian phar-
macoeconomic guidelines. Robustness was tested using one-way and probabilistic 
sensitivity analyses with 10,000 iterations. Results: Respective expected costs 
were 132,730€ , 135,187€ , 135,413€ , 138,412€ , 151,457€ and 165,636€ ; respective QALYs 
were 6.598, 6.673, 6.656, 6.690, 6.760 and 6.832. UST/ADA/INF had the lowest cost. 
UST/INF/ADA and ADA/INF/UST were dominated. ICERs for the remaining strate-
gies were ADA/UST/INF:32,568€ , INF/ADA/UST:187,113€ and INF/UST/ADA:197,929€ . 
Despite adding a few more QALYs, all ICERs fell well above the 2014 NICE thresh-
old for cost-effectiveness (24,800€ ). Overall, the model was sensitive to changes in 
drug prices. Starting with UST potentially saves 41.7€ million over starting with 
ADA and 318€ million over starting with INF in the 17,000 patients eligible for bio-
logicals. cOnclusiOns: In Russia, the cost-effective approach for patients with 
moderate-to-severe PsA that failed DMARDs is to initiate biologic therapy with UST, 
use ADA as second line and INF as third line.
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Objectives: To assess the cost-utility of Tocilizumab (TCZ) in the treatment 
of methotrexate (MTX)-naïve adults with active rheumatoid arthritis (RA) in 
Slovakia. MethOds: A decision tree model was developed to reflect the early 
management of MTX-naïve adult RA patients in Slovakia. Efficacy, DAS28 remis-
sion, for each treatment in the model was derived from a network meta-analysis 
(NMA) of randomised controlled trials (RCTs) [Sawyer et al. 2015]. Benefits were 
measured in Quality Adjusted Life years (QALYs) derived by mapping DAS28 scores 
onto EQ-5D utility weights. The analysis was conducted from the third-party payer 
perspective, and included direct medical costs (drugs, administration, monitoring). 
The time horizon is one year, in line with the maximum follow-up period from 
RCTs. Incremental costs and QALYs associated with TCZ±MTX were compared to 
anti-tumour necrosis factors (TNFs), including adalimumab (ADA), etanercept (ETN) 
and infliximab (IFX), within their licensed indications. Each treatment was also 
compared to MTX alone. Variables related to efficacy, cost and utility were tested in 
the sensitivity analysis. Results: TCZ±MTX had a lower incremental cost-effec-
tiveness ratio (ICER) than other TNFs ±MTX when compared to MTX alone in base 
case. When compared head-to-head with TNFs, TCZ was cost-effective, with ICERs 
range from € 6,500 to € 16,000 per QALY gained in monotherapy and from € 10,000 
to € 24,000 per QALY gained in combination therapy. Furthermore, TCZ+MTX domi-
nated IFX+MTX. The full incremental analysis showed that TCZ±MTX was the next 
most cost-effective strategy after MTX. Results of the sensitivity analysis showed 
the efficacy variables and the assumption on the utility mapping formula have an 
impact on the ICERs. cOnclusiOns: The results suggest TCZ is a cost-effective 
alternative to the approved and reimbursed TNFs, used either as monotherapy or in 
combination with MTX in the treatment of MTX-naïve adult RA patients in Slovakia.
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Objectives: Proton pump inhibitors (PPI) are not always added to the treatment of 
low dose acetylsalicylic acid (LDASA), but is proven to be effective in preventing upper 
gastrointestinal toxicity. However, PPI’s may also have additional side effects that 
